secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0001193125-24-107015
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin settles derivative suits; governance reforms and up to $1.25M fee cap
------------------------------------------------------------------------------

- Settlement resolves Wang v. Bienaimé and Tsantes v. Bienaimé derivative actions in Delaware Chancery Court.
- BioMarin to implement corporate governance reforms (Exhibit A) for at least four years.
- BioMarin will not oppose plaintiffs' counsel fee award not to exceed $1.25 million.
- No admission of wrongdoing; defendants continue to deny all claims.
- Settlement is subject to final approval by the Delaware Court of Chancery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524107015/0001193125-24-107015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524107015/d797498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-107015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer